Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma

医学 长春新碱 奥比努图库单抗 美罗华 切碎 内科学 危险系数 弥漫性大B细胞淋巴瘤 胃肠病学 肿瘤科 环磷酰胺 中性粒细胞减少症 淋巴瘤 化疗 强的松 置信区间
作者
Umberto Vitolo,Marek Trněný,David Belada,John M. Burke,Angelo Michele Carella,Neil Sun Chua,Pau Abrisqueta,Judit Demeter,Ian W. Flinn,Xiaonan Hong,Won Seog Kim,Antonio Pinto,Yuankai Shi,Yoichi Tatsumi,Mikkel Z. Oestergaard,Michael Wenger,Günter Fingerle‐Rowson,Olivier Catalani,Tina G. Nielsen,Maurizio Martelli
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:35 (31): 3529-3537 被引量:450
标识
DOI:10.1200/jco.2017.73.3402
摘要

Purpose Rituximab (R) plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy is the standard of care in previously untreated diffuse large B-cell lymphoma (DLBCL). Obinutuzumab (G) is a glycoengineered, type II, anti-CD20 monoclonal antibody. GOYA was a randomized phase III study that compared G-CHOP with R-CHOP in patients with previously untreated advanced-stage DLBCL. Methods Patients (N = 1,418) were randomly assigned to receive eight 21-day cycles of G (n = 706) or R (n = 712), plus six or eight cycles of CHOP. Primary end point was investigator-assessed progression-free survival (PFS). Results After median observation of 29 months, the number of investigator-assessed PFS events was similar between G (201; 28.5%) and R (215; 30.2%), stratified hazard ratio was 0.92 (95% CI, 0.76 to 1.11; P = .39), and 3-year PFS rates were 70% and 67%, respectively. Secondary end points of independently reviewed PFS, other time-to-event end points, and tumor response rates were similar between arms. In exploratory subgroup analyses, patients with germinal-center B cell-like subtype had a better PFS than did patients with activated B cell-like subtype, irrespective of treatment. Frequencies of grade 3 to 5 adverse events (AEs; 73.7% v 64.7%, respectively) and serious AEs (42.6% v 37.6%, respectively) were higher with G-CHOP compared with R-CHOP. Fatal AE frequencies were 5.8% for G-CHOP and 4.3% for R-CHOP. The most common AEs were neutropenia (G-CHOP, 48.3%; R-CHOP, 40.7%), infusion-related reactions (G-CHOP, 36.1%; R-CHOP, 23.5%), nausea (G-CHOP, 29.4%; R-CHOP, 28.3%), and constipation (G-CHOP, 23.4%; R-CHOP, 24.5%). Conclusion G-CHOP did not improve PFS compared with R-CHOP in patients with previously untreated DLBCL. AEs reported with G were consistent with the known safety profile. Biomarker analyses may help define a future role for G in DLBCL.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
bkagyin的应助被撒拉嘿呀噻采纳,获得10
2秒前
Liu发布了新的文献求助30
2秒前
畅快访蕊完成签到,获得积分20
3秒前
优美的梦岚的应助被木叶流2022采纳,获得10
4秒前
5秒前
wanci的应助被路lu采纳,获得10
5秒前
ghost完成签到,获得积分10
6秒前
研友_VZG7GZ的应助被机智宛亦采纳,获得10
7秒前
kiluto发布了新的文献求助10
8秒前
8秒前
8秒前
8秒前
LynShen完成签到 ,获得积分20
8秒前
11秒前
11秒前
科研通AI65的应助被Mortal采纳,获得10
11秒前
11秒前
11秒前
为了精彩的活完成签到,获得积分10
11秒前
二三发布了新的文献求助10
12秒前
蒲公英完成签到 ,获得积分10
13秒前
哭泣雅绿发布了新的文献求助10
13秒前
英俊的铭的应助被动听的翠桃采纳,获得10
14秒前
hhh完成签到 ,获得积分20
15秒前
机灵语山完成签到,获得积分10
15秒前
wwwwww完成签到,获得积分10
15秒前
15秒前
huangping发布了新的文献求助20
15秒前
丘比特的应助被联网中请稍等采纳,获得10
16秒前
16秒前
充电宝的应助被Fern采纳,获得10
17秒前
Maestro_S的应助被鱼鱼鱼采纳,获得10
17秒前
123关闭了123的文献求助
18秒前
西柚宝宝完成签到,获得积分10
18秒前
怕孤独的飞槐完成签到 ,获得积分10
18秒前
刘扣扣UU的应助被机灵语山采纳,获得10
20秒前
丘比特的应助被kiluto采纳,获得10
21秒前
22秒前
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192723
求助须知:如何正确求助?哪些是违规求助? 9579144
关于积分的说明 21863903
捐赠科研通 7792268
什么是DOI,文献DOI怎么找? 3437013
关于科研通互助平台的介绍 2560633
邀请新用户注册赠送积分活动 2483864